Related Experiment Video
Updated: Jun 10, 2025

Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells
Published on: June 13, 2019
Phosphorylation strongly affects the inhibition of human carbonic anhydrase I CO2 hydration activity
Andrea Angeli1, Vivian De Luca2, Xiaojing Huang3
1Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy.
Insights
Phosphorylation at Ser51 significantly alters human carbonic anhydrase I (hCA I) function, reducing its catalytic efficiency and dramatically changing its sensitivity to inhibitors. This impacts understanding of hCA I
Area of Science:
- Biochemistry
- Enzymology
- Molecular Biology
Background:
- Human carbonic anhydrases (hCAs) are crucial for physiological processes and implicated in various diseases.
- Human CA I (hCA I) is abundant in erythrocytes and vital for CO2 transport.
- The impact of post-translational modifications (PTMs), especially phosphorylation, on hCA I activity and inhibitor binding is poorly understood.
Purpose of the Study:
- To investigate the functional consequences of phosphorylation at the conserved Ser51 residue in hCA I.
- To examine the effects of a phosphomimetic mutation (S51E) on hCA I's catalytic efficiency and inhibitor susceptibility.
Main Methods:
- Utilized a recombinant expression system to produce wild-type and S51E mutant hCA I.
- Employed stopped-flow kinetic assays to measure CO2 hydration activity.
- Assessed inhibition kinetics using a panel of 41 sulfonamides and 37 small anions.
Main Results:
- The S51E mutation increased catalytic turnover (kcat) but significantly decreased substrate affinity (KM), reducing overall catalytic efficiency by over 50%.
- S51E hCA I showed dramatically altered sensitivity to sulfonamide inhibitors, with the most effective inhibitors becoming over 35-fold less potent.
- The mutant exhibited significantly reduced susceptibility to 24 out of 37 tested anions, with some KIs increasing up to 11,000-fold.
Conclusions:
- Phosphorylation at Ser51 profoundly impacts hCA I's catalytic activity and inhibitor binding profile.
- These findings highlight the importance of considering PTMs for understanding enzyme function and drug development.
- Characterizing proteoform-specific inhibition is a key step towards developing more targeted therapies for carbonic anhydrase-related diseases.
Abstract:
Human carbonic anhydrases (hCAs) have essential roles in respiration, acid-base balance, and fluid secretion, with implications in diseases such as glaucoma, epilepsy, obesity, and cancer. Of the fifteen known hCAs, human CA I (hCA I) is particularly abundant in erythrocytes, playing a critical role in CO2 transport. Despite extensive research on hCA I, the impact of post-translational modifications (PTMs), particularly phosphorylation, on its catalytic activity and inhibitor binding remains poorly understood. Although multiple phosphorylation sites have been identified in hCA I in vivo through high-throughput proteomics studies including at the highly conserved Ser51 residue, the functional consequences of these modifications are not well characterized. We investigated the effects of a phosphomimetic mutation at Ser51 on hCA I, examining its catalytic efficiency and susceptibility to inhibition by sulfonamides and anions. Using a recombinant expression system and a stopped-flow kinetic assay, we characterized the CO2 hydration activity and inhibition profiles of S51E hCA I compared to the wild type enzyme. Our results demonstrate that the S51E mutation increases the catalytic turnover rate (kcat) from 2.0 × 105 s-1 to 2.6 × 105 s-1 but significantly decreases substrate affinity, raising the Michaelis constant (KM) from 4.0 mM to 13.9 mM, reducing overall catalytic efficiency by over 50 %. Inhibition studies with a panel of 41 sulfonamides revealed that the S51E mutation dramatically alters inhibitor sensitivity, particularly for the most effective inhibitors. For example, 15 of the 16 most effective sulfonamide inhibitors for hCA I (with KIs <350 nM) were an average of over 35-fold less effective in inhibiting S51E hCA I than the wild type. The KI of the anticonvulsant zonisamide increased from 31 nM for the wild type hCA I to 4.0 μM. The inhibition profile with a panel of 37 small anions further indicated that the S51E mutant exhibited significantly reduced susceptibility to inhibition by 24 out of 37 tested anions, with some KI values increasing by up to 11,000-fold for inhibitors like hydrogen sulfide. This study underscores the significant impact that phosphorylation may have on hCA I function and inhibition. By characterizing the effects of phosphorylation on the CO2 hydration activity and inhibitor sensitivity of hCA I, these findings represent early steps in developing more selective proteoform-specific inhibitors, which could lead to more effective treatments for diseases involving carbonic anhydrases.
Related Concept Videos
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Bicarbonate-Carbonic Acid Buffer
GPCRs Regulate Adenylyl Cylase Activity
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...

